MiR-630 was also found to be upregulated in head and neck squamous cell carcinoma after cisplatin treatment and can modulate the protein expression of ATG5, ATG6/BECN1, ATG10, ATG12, ATG16L1 and UVRAG [32], [33]. This evidence concerns the gene ATG16L1 and head and neck squamous cell carcinoma.